Company: SNWV
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050280
Chunk: 98

Company: SANUWAVE Health, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 98
---
 due to increased headcount expenses of $2.2 million, partially offset by a decrease in outside commission expense of $1.3 million.

Research and Development

Research and development expenses for the three months ended September 30, 2025 were $0.3 million compared to $0.2 million for the three months ended September 30, 2024. The research and development costs in the three months ended September 30, 2025, remained approximately consistent with the costs in the same period of 2024.

Research and development expenses for the nine months ended September 30, 2025 were $0.7 million compared to $0.5 million for the nine months ended September 30, 2024. The research and development costs in the nine months ended September 30, 2025, remained approximately consistent with the costs in the same period of 2024.

27

Total Other Income (Expense)

Other income (expense) consists of the following:

Three Months Ended September 30,ChangeNine Months Ended September 30,Change20252024$%20252024$%Interest expense$(1,722)$(3,661)$1,939 53%$(5,448)$(11,004)$5,556 50%Change in fair value of derivative liabilities6,097 (18,849)24,946 132%2,186 (17,633)19,819 112%Gain (Loss) on extinguishment of debt(477)- (477)-%(477)5,205 (5,682)109%Loss on impairment of assets(196)- (196)-%(196)- (196)-%Other expense(14)(106)92 87%(42)(893)851 95%Other income5,170 6 5,164 86067%5,351 2,806 2,545 91%Total Other Income (Expense)$8,858 $(22,610)$31,468 139%$1,374 $(21,519)$22,893 106%

Total other income (expense) increased by $31.5 million to other income of $8.9 million for the three months ended September 30, 2025, as compared to an expense of $22.6 million for the same period of 2024. The increase was primarily driven by the change in fair value of derivative liabilities of $24.9 million and other income of